How Cabozantinib is Being Used in Practice for Patients With RCC

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

ALLO-316 demonstrated a 50% overall response rate and 33% complete response rate in CD70-positive advanced RCC in the phase 1 TRAVERSE trial.

Casdatifan showed notable clinical activity and an acceptable safety profile in treating patients with metastatic clear cell renal cell carcinoma.